As the file enclosed.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venus Remedies Ltd reported strong FY2026 audited results with standalone revenue from operations of Rs. 768.73 crore, up 19.3% from Rs. 644.47 crore in FY25. Net profit jumped 89% to Rs. 99.31 crore from Rs. 52.55 crore, while consolidated net profit grew 127% to Rs. 102.78 crore. EBITDA rose 71% to Rs. 155.37 crore on standalone basis. The Board recommended a final dividend of Rs. 10 per share (100%) subject to shareholder approval at the 37th AGM on August 20, 2026 (record date: August 7, 2026). Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated results. The company has a German subsidiary (Venus Pharma GmbH) and a step-down Hungarian subsidiary.
Venus Remedies delivered exceptional double-digit growth in both revenue and profitability, with EBITDA margin expansion indicating improved operational efficiency. The clean audit opinion and positive cash flows from operations (Rs. 151 crore standalone) signal financial health, supporting bullish sentiment for the stock ahead of the dividend payout.